Opinion|Videos|August 13, 2024
Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment
In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of development and expected impact on treatment algorithms, while also considering future changes in coverage and payer strategies with the emergence of new therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Where do you see certain prescriptions fitting into treatment algorithms for patients living with chronic spontaneous urticaria (CSU)?
a. Given the data you’ve seen to date, how would you advise managed
- Another Bruton tyrosine kinase inhibitor, rilzabrutinib, is also under investigation for patients living with CSU. What stage of development is this molecule in and what has the data demonstrated?
- How do you see treatment algorithms changing in the future with the introduction of newer classes of therapies?
a. With potential new treatment options on the horizon, how do you think payers should anticipate covering CSU in the next few years?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Across the US, Obesity Care Still Lacks an Owner
3
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
4
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
5